Allarity Therapeutics, INC 8-K filings

Allarity Therapeutics announced the grant of a key U.S. patent for its stenoparib-specific Drug Response Predictor (DRP) companion diagnostic, extending protection until April 2042.

Allarity Therapeutics, Inc. has amended its Management Services Agreement with Ljungaskog Consulting AB, owned by CEO Thomas H. Jensen, adjusting compensation and termination terms.

Allarity Therapeutics announced CEO Thomas Jensen will present clinical data on its dual PARP/WNT inhibitor, stenoparib, at the Precision Medicine Forum Europe 2026.

Allarity Therapeutics announced its API manufacturing campaign for stenoparib is on track for completion by Q3 2026, supporting pivotal trial development.

Allarity Therapeutics announced a Notice of Allowance from the USPTO for its DRP companion diagnostic specific to stenoparib, expected to grant exclusivity into 2039.

Allarity Therapeutics announced the presentation of two scientific posters at the AACR Annual Meeting 2026, highlighting stenoparib's potential in colorectal cancer and linking its companion diagnostic to improved survival in ovarian cancer.

Allarity Therapeutics announced its full year 2025 financial results, highlighting a strengthened financial position, FDA Fast Track designation for stenoparib, and extended cash runway into mid-2028.

Allarity Therapeutics, Inc. has entered into a note purchase agreement with Streeterville Capital, LLC for $20 million in new debt financing, subject to significant discounts, high interest rates, and stringent covenants.

Allarity Therapeutics announced the dosing of first patients in a VA-funded Phase 2 trial for relapsed small cell lung cancer using stenoparib and temozolomide.

Allarity Therapeutics announced the opening of enrollment for its Phase 2 clinical trial, fully funded by the U.S. Department of Veterans Affairs, evaluating stenoparib in combination with temozolomide for recurrent small cell lung cancer.

Allarity Therapeutics, Inc. has entered into a Common Stock Purchase Agreement with Tumim Stone Capital LLC, providing access to up to $6 million in equity financing.

Allarity Therapeutics, Inc. announced the additional closing of a private placement, raising approximately $250,000 through the sale of 255,103 common shares.

Allarity Therapeutics, Inc. has formalized Jeffrey S. Ervin's transition to full-time Chief Financial Officer with a new employment agreement, detailing his compensation and responsibilities.

Allarity Therapeutics announced new Phase 2 clinical data for stenoparib, showing median Overall Survival in advanced ovarian cancer patients has surpassed 25 months, significantly exceeding current FDA-approved therapies.

Allarity Therapeutics, Inc. announced a private placement of common stock and pre-funded warrants, raising approximately $2.5 million, with an option for an additional $7.5 million.

Allarity Therapeutics' CEO, Thomas Jensen, will present on its DRP companion diagnostic and stenoparib at the Biomarkers & Precision Medicine 2025 conference in London.

Allarity Therapeutics announced that its investigational drug stenoparib received FDA Fast Track designation for advanced ovarian cancer, aiming to expedite development and review.

Allarity Therapeutics, Inc. announced a new commercial agreement with an EU-based biotechnology company, licensing its DRP algorithms for breast cancer and providing laboratory services, validating its precision oncology platform.

Allarity Therapeutics, Inc. announced the resignation of its Chief Financial Officer, Alexander Epshinsky, effective June 30, 2025, and the appointment of Jeffrey S. Ervin as the new part-time CFO, effective July 1, 2025.

Allarity Therapeutics, Inc. announced that IP Australia has formally accepted its patent application for the Drug Response Predictor (DRP) companion diagnostic specific to its cancer treatment, stenoparib, marking a significant step in its global intellectual property strategy.

Allarity Therapeutics, Inc. announced the dosing of the second patient in its new Phase 2 clinical trial evaluating stenoparib for advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer, signaling rapid trial enrollment.

Allarity Therapeutics, Inc. announced the results of its annual meeting of stockholders held on June 13, 2025, where a Class III director was elected and the independent auditor was ratified, but proposals to significantly increase the equity incentive plan and limit officer liability were not approved.

Allarity Therapeutics, a Phase 2 clinical-stage pharmaceutical company, announced the appointment of Jesper Hiland to its Board of Directors, replacing Joseph Vazzano, effective June 30, 2025.

Allarity Therapeutics, a Phase 2 clinical-stage pharmaceutical company, announced a research collaboration with the Indiana Biosciences Research Institute (IBRI) to deepen the understanding of stenoparib's unique dual mechanism of action as a personalized cancer treatment.

Allarity Therapeutics, Inc. announced the enrollment of the first patient in its new Phase 2 clinical trial protocol for stenoparib, targeting advanced, platinum-resistant or platinum-ineligible ovarian cancer, aiming to accelerate development and validate its DRP companion diagnostic.

Allarity Therapeutics announces its CEO, Thomas Jensen, will present a company overview at the Pharma Partnering Summit US, focusing on stenoparib and the DRP companion diagnostic platform.

Allarity Therapeutics highlights continued clinical benefit of Stenoparib in ovarian cancer, initiates share repurchase program, and reports $27 million in cash for Q1 2025.

Allarity Therapeutics announces the presentation of a poster at the AACR 2025 Annual Meeting showcasing a novel Drug Response Predictor (DRP) designed to identify multiple myeloma patients likely to benefit from daratumumab.

Allarity Therapeutics reclassifies a director to balance board membership and sets the date for its 2025 annual meeting of stockholders.

Allarity Therapeutics announces its full year 2024 financial results, reporting a strengthened cash position expected to fund operations into 2027 and progress in its stenoparib clinical development program.